United States Biotechnology & Medical Research

Neximmune Inc (NEXI)

Track

Ticker: NEXI Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Neximmune Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.2
Roemer Alan S. Director Non-Executive Director
Transaction date
Proposed sale
Price
33.01
Quantity 77,608
Value US$931,297
2.2
Roemer Alan S. Non-Executive Director
Transaction date
Sale
Price
482.46
Quantity 83,733 -48.7%
Value US$2,696,092
2.2
Roemer Alan S. Director Non-Executive Director
Transaction date
Proposed sale
Price
406.38
Quantity 61,427
Value US$1,586,900
2.2
Roemer Alan S. Non-Executive Director
Transaction date
Sale
Price
2.16
Quantity 3,833 -49.0%
Value US$8,287
2.2
Roemer Alan S. Director Non-Executive Director
Transaction date
Proposed sale
Price
2.09
Quantity 7,825
Value US$16,354
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
0.48
Quantity 75,000 +4.3%
Value US$35,918
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
0.48
Quantity 125,000 +7.7%
Value US$60,300
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
2.28
Quantity 26,876 +2.5%
Value US$61,385
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
2.14
Quantity 25,000 +2.4%
Value US$53,538
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
2.22
Quantity 15,000 +1.4%
Value US$33,374
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.22
Quantity 20,720 +1.3%
Value US$46,100
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
2.23
Quantity 47,900 +4.8%
Value US$106,683
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.35
Quantity 40,000 +2.6%
Value US$94,160
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
2.38
Quantity 40,200 +4.2%
Value US$95,760
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.19
Quantity 39,280 +2.6%
Value US$85,894
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
2.11
Quantity 45,024 +5.0%
Value US$95,118
0.5
Jones Kristi President and CEO Executive Director
Transaction date
Purchase
Price
3.74
Quantity 10,000 +15.9%
Value US$37,400
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
3.76
Quantity 18,983 +2.1%
Value US$71,376
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
4.14
Quantity 131,622 +17.4%
Value US$544,915
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
3.35
Quantity 39,995 +5.6%
Value US$133,983
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.67
Quantity 10,000 +0.7%
Value US$26,653
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.41
Quantity 30,000 +2.0%
Value US$72,300
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.14
Quantity 30,000 +2.1%
Value US$64,080
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
2.11
Quantity 30,000 +2.1%
Value US$63,210
1.6
BARER SOL J Non-Executive Director
Transaction date
Purchase
Price
17.00
Quantity 60,000 +4.1%
Value US$1,020,000
0.5
Jones Kristi Chief Operating Officer Officer
Transaction date
Purchase
Price
17.00
Quantity 911 +1.5%
Value US$15,487
1.2
Verstandig Grant Non-Executive Director
Transaction date
Purchase
Price
17.00
Quantity 175,000 +32.4%
Value US$2,975,000
3.1
ZELDIS JEROME B Executive VP of Research & Dev Officer
Transaction date
Purchase
Price
17.00
Quantity 5,882 +inf%
Value US$99,994
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-11-22 2023-11-22 PrS Proposed sale
2.2
Roemer Alan S.

Director

Non-Executive Director
77,608
33.01
US$931,297 		77,608 33.01 US$931,297
2023-11-22 2023-11-22 S Sale
2.2
Roemer Alan S.
Non-Executive Director
83,733 -48.7%
482.46
US$2,696,092 		83,733 -48.7% 482.46 US$2,696,092
2023-11-22 2023-11-21 PrS Proposed sale
2.2
Roemer Alan S.

Director

Non-Executive Director
61,427
406.38
US$1,586,900 		61,427 406.38 US$1,586,900
2023-11-22 2023-11-21 S Sale
2.2
Roemer Alan S.
Non-Executive Director
3,833 -49.0%
2.16
US$8,287 		3,833 -49.0% 2.16 US$8,287
2023-11-21 2023-11-21 PrS Proposed sale
2.2
Roemer Alan S.

Director

Non-Executive Director
7,825
2.09
US$16,354 		7,825 2.09 US$16,354
2022-11-17 2022-11-17 B Purchase
1.6
BARER SOL J
Non-Executive Director
75,000 +4.3%
0.48
US$35,918 		75,000 +4.3% 0.48 US$35,918
2022-11-17 2022-11-16 B Purchase
1.6
BARER SOL J
Non-Executive Director
125,000 +7.7%
0.48
US$60,300 		125,000 +7.7% 0.48 US$60,300
2022-06-07 2022-06-07 B Purchase
1.2
Verstandig Grant
Non-Executive Director
26,876 +2.5%
2.28
US$61,385 		26,876 +2.5% 2.28 US$61,385
2022-06-07 2022-06-06 B Purchase
1.2
Verstandig Grant
Non-Executive Director
25,000 +2.4%
2.14
US$53,538 		25,000 +2.4% 2.14 US$53,538
2022-06-07 2022-06-03 B Purchase
1.2
Verstandig Grant
Non-Executive Director
15,000 +1.4%
2.22
US$33,374 		15,000 +1.4% 2.22 US$33,374
2022-06-02 2022-06-02 B Purchase
1.6
BARER SOL J
Non-Executive Director
20,720 +1.3%
2.22
US$46,100 		20,720 +1.3% 2.22 US$46,100
2022-06-02 2022-06-02 B Purchase
1.2
Verstandig Grant
Non-Executive Director
47,900 +4.8%
2.23
US$106,683 		47,900 +4.8% 2.23 US$106,683
2022-06-02 2022-06-01 B Purchase
1.6
BARER SOL J
Non-Executive Director
40,000 +2.6%
2.35
US$94,160 		40,000 +2.6% 2.35 US$94,160
2022-06-02 2022-06-01 B Purchase
1.2
Verstandig Grant
Non-Executive Director
40,200 +4.2%
2.38
US$95,760 		40,200 +4.2% 2.38 US$95,760
2022-06-02 2022-05-31 B Purchase
1.6
BARER SOL J
Non-Executive Director
39,280 +2.6%
2.19
US$85,894 		39,280 +2.6% 2.19 US$85,894
2022-06-02 2022-05-31 B Purchase
1.2
Verstandig Grant
Non-Executive Director
45,024 +5.0%
2.11
US$95,118 		45,024 +5.0% 2.11 US$95,118
2022-03-30 2022-03-29 B Purchase
0.5
Jones Kristi

President and CEO

Executive Director
10,000 +15.9%
3.74
US$37,400 		10,000 +15.9% 3.74 US$37,400
2022-03-28 2022-03-28 B Purchase
1.2
Verstandig Grant
Non-Executive Director
18,983 +2.1%
3.76
US$71,376 		18,983 +2.1% 3.76 US$71,376
2022-03-28 2022-03-25 B Purchase
1.2
Verstandig Grant
Non-Executive Director
131,622 +17.4%
4.14
US$544,915 		131,622 +17.4% 4.14 US$544,915
2022-03-28 2022-03-24 B Purchase
1.2
Verstandig Grant
Non-Executive Director
39,995 +5.6%
3.35
US$133,983 		39,995 +5.6% 3.35 US$133,983
2022-03-24 2022-03-23 B Purchase
1.6
BARER SOL J
Non-Executive Director
10,000 +0.7%
2.67
US$26,653 		10,000 +0.7% 2.67 US$26,653
2022-03-23 2022-03-22 B Purchase
1.6
BARER SOL J
Non-Executive Director
30,000 +2.0%
2.41
US$72,300 		30,000 +2.0% 2.41 US$72,300
2022-03-22 2022-03-21 B Purchase
1.6
BARER SOL J
Non-Executive Director
30,000 +2.1%
2.14
US$64,080 		30,000 +2.1% 2.14 US$64,080
2022-03-21 2022-03-18 B Purchase
1.6
BARER SOL J
Non-Executive Director
30,000 +2.1%
2.11
US$63,210 		30,000 +2.1% 2.11 US$63,210
2021-02-19 2021-02-17 B Purchase
1.6
BARER SOL J
Non-Executive Director
60,000 +4.1%
17.00
US$1,020,000 		60,000 +4.1% 17.00 US$1,020,000
2021-02-19 2021-02-17 B Purchase
0.5
Jones Kristi

Chief Operating Officer

Officer
911 +1.5%
17.00
US$15,487 		911 +1.5% 17.00 US$15,487
2021-02-19 2021-02-17 B Purchase
1.2
Verstandig Grant
Non-Executive Director
175,000 +32.4%
17.00
US$2,975,000 		175,000 +32.4% 17.00 US$2,975,000
2021-02-19 2021-02-17 B Purchase
3.1
ZELDIS JEROME B

Executive VP of Research & Dev

Officer
5,882 +inf%
17.00
US$99,994 		5,882 +inf% 17.00 US$99,994
Explore more

More insider trading research around Neximmune Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America